Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | ASCO GU 2024: immunotherapy highlights in kidney cancer

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT, discusses his highlights presented at the ASCO GU Cancers Symposium 2024 in the field of kidney cancer, including overall survival data from trials assessing pembrolizumab and nivolumab, as well as outcomes in patients receiving belzutifan. Dr Braun additionally comments on the optimal administration route of nivolumab. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.